There have been severalreports of Hsp90 CTD inhibitors with anticancer activity against HER2-positivebreast cancer as well as TNBC,37−40 but most of them are analogs of known natural productssuch as deguelin (Figure 1). This evidence concerns the gene HSP90AB1 and cancer.